WO2005101004A3 - Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1) - Google Patents

Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1) Download PDF

Info

Publication number
WO2005101004A3
WO2005101004A3 PCT/EP2005/003410 EP2005003410W WO2005101004A3 WO 2005101004 A3 WO2005101004 A3 WO 2005101004A3 EP 2005003410 W EP2005003410 W EP 2005003410W WO 2005101004 A3 WO2005101004 A3 WO 2005101004A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
purinoceptor
therapeutics
diagnostics
type
Prior art date
Application number
PCT/EP2005/003410
Other languages
French (fr)
Other versions
WO2005101004A8 (en
WO2005101004A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005101004A2 publication Critical patent/WO2005101004A2/en
Publication of WO2005101004A3 publication Critical patent/WO2005101004A3/en
Publication of WO2005101004A8 publication Critical patent/WO2005101004A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention provides a human P2Y1 which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of P2Y1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/003410 2004-04-13 2005-04-01 Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1) WO2005101004A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04008717 2004-04-13
EP04008717.3 2004-04-13

Publications (3)

Publication Number Publication Date
WO2005101004A2 WO2005101004A2 (en) 2005-10-27
WO2005101004A3 true WO2005101004A3 (en) 2006-04-27
WO2005101004A8 WO2005101004A8 (en) 2006-06-22

Family

ID=34963251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003410 WO2005101004A2 (en) 2004-04-13 2005-04-01 Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1)

Country Status (1)

Country Link
WO (1) WO2005101004A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200179530A1 (en) * 2016-05-19 2020-06-11 University Of Miami Targeted delivery of therapeutic agents and imaging reagents to pancreatic cancer cells

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090117A2 (en) * 2000-05-19 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the p2ry1 gene
WO2002014511A2 (en) * 2000-08-14 2002-02-21 Bayer Aktiengesellschaft Regulation of human p2y1-like g protein-coupled receptor
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
WO2003016475A2 (en) * 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
WO2003101284A2 (en) * 2002-06-04 2003-12-11 Metabolex, Inc. Methods of diagnosing and treating diabetes and insulin resistance
WO2004035732A2 (en) * 2002-08-29 2004-04-29 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
WO2004040000A2 (en) * 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
US20040010136A1 (en) * 1998-01-30 2004-01-15 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
WO2001090117A2 (en) * 2000-05-19 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the p2ry1 gene
WO2002014511A2 (en) * 2000-08-14 2002-02-21 Bayer Aktiengesellschaft Regulation of human p2y1-like g protein-coupled receptor
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2003016475A2 (en) * 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
WO2003101284A2 (en) * 2002-06-04 2003-12-11 Metabolex, Inc. Methods of diagnosing and treating diabetes and insulin resistance
WO2004035732A2 (en) * 2002-08-29 2004-04-29 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
WO2004040000A2 (en) * 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof

Also Published As

Publication number Publication date
WO2005101004A8 (en) 2006-06-22
WO2005101004A2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2006005469A3 (en) Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2005101001A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005101004A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2006008003A3 (en) Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005101011A3 (en) Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
WO2006040047A3 (en) Diagnostics and therapeutics for diseases associated with rho/rac-interacting citron kinase (cit)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2006013012A3 (en) Diagnostics and therapeutics for diseases associated with napsin 1 (nap1)
WO2005095631A3 (en) Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)
WO2006005461A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 27 (gpr27)
WO2006010497A3 (en) Diagnostics and therapeutics for diseases associated with choline kinase (chk)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase